Amicus Therapeutics is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class treatments in development for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases (LSDs).

Publications show all

Amicus Therapeutics has published 29 articles.

Patents show all

261Applications133Issued

Clinical Trials show all

11Phase 27Phase 16Phase 33N/A1Other

SEC Filings show all

8-K14810-Q2910-K11D6S-11

Private Funding Events

DateOfferedSoldType
2013-12-03$15,000,000$15,000,000Equity
2013-12-03$15,000,000$15,000,000Equity, Option to Acquire
2012-07-30$18,582,360$18,582,360Equity
2010-11-05$31,284,583$31,284,583Equity
2007-05-25UnknownUnknownOther (Paper Filing)

Key Executives

  • John F Crowley
    Executive Officer, Director
  • Matthew R Patterson
    Executive Officer
  • David Lockhart
    Executive Officer
  • Pol F Boudes
    Executive Officer
  • Geoffrey P Gilmore
    Executive Officer
  • S Nicole Schaeffer
    Executive Officer
  • Bradley L Campbell
    Executive Officer
  • John R Kirk
    Executive Officer
  • Ken Valenzano
    Executive Officer
  • James Barrett
    Director
  • Sol J Barer
    Director
  • Alexander E Barkas
    Director
  • Donald J Hayden
    Director
  • Margaret G McGlynn
    Director
  • P Sherrill Neff
    Director
  • Michael G Raab
    Director
  • Glenn P Sblendorio
    Director
  • James N Topper
    Director
  • John F. Crowley
    Executive Officer, Director
  • David J. Lockhart
    Executive Officer
  • Pol F. Boudes
    Executive Officer
  • Bradley L. Campbell
    Executive Officer
  • William D. Baird, III
    Executive Officer
  • Donald J. Hayden, Jr.
    Director
  • Sol J. Barer
    Director
  • Margaret G. McGlynn
    Director
  • Michael G. Raab
    Director
  • Glenn Sblendorio
    Director
  • James N. Topper
    Director
  • Ted W. Love
    Director
  • Robert Essner
    Director
  • Daphne Quimi
    Executive Officer
  • John R. Kirk
    Executive Officer
  • Enrique Dilone
    Executive Officer
  • Kenneth W. Peist
    Executive Officer
  • Robert Winkler
    Executive Officer
  • Joan C. Winterbottom
    Executive Officer
  • Jayne Gerskowitz
    Executive Officer
  • Jeffrey P. Castelli
    Executive Officer
  • Jeffrey Castelli
    Executive Officer